Y-Intercept (HK)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Y-Intercept (HK)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.84M	Buy	55,833 +49,087	+728%	+$6.64M	0.17%	117
2026 Q1	$862K	Buy	+6,746	New	+$842K	0.02%	1090
2025 Q4	–	Sell	-18,828	Closed	-$1.89M	–	2039
2025 Q3	$1.89M	Buy	18,828 +12,242	+186%	+$1.1M	0.05%	640
2025 Q2	$546K	Buy	+6,586	New	+$525K	0.01%	1176
2024 Q3	–	Sell	-9,083	Closed	-$842K	–	1872
2024 Q2	$842K	Buy	9,083 +392	+5%	+$35.1K	0.05%	571
2024 Q1	$825K	Buy	+8,691	New	+$806K	0.06%	466
2023 Q1	–	Sell	-3,222	Closed	-$267K	–	1592
2022 Q4	$267K	Sell	3,222 -1,283	-28%	-$104K	0.04%	713
2022 Q3	$357K	Buy	+4,505	New	+$380K	0.04%	644
2021 Q2	–	Sell	-7,351	Closed	-$956K	–	948
2021 Q1	$956K	Buy	+7,351	New	+$1.1M	0.26%	105

Other funds holding XBI

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

NHFG

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

LRPA

L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Y-Intercept (HK)'s XBI Position: Q2 2026 in Review

Y-Intercept (HK) increased its State Street SPDR S&P Biotech ETF (XBI) stake by 728% in Q2 2026, buying an estimated $6.64M and bringing the position to 55,833 shares worth $8.84M. The position accounts for 0.17% of the portfolio, ranked #117.

Y-Intercept (HK) first reported a position in XBI in Q1 2021 and has held it in 9 quarters since. 225 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Y-Intercept (HK) held 55,833 shares of State Street SPDR S&P Biotech ETF worth $8.84M as of Q2 2026.
Y-Intercept (HK) bought 49,087 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.64M.
State Street SPDR S&P Biotech ETF made up 0.17% of Y-Intercept (HK)'s portfolio in Q2 2026, its #117 holding.
Y-Intercept (HK) first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and has held it in 9 quarters since.
225 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.